CodeMap®  150 North Wacker Drive
Suite 1870
Chicago, IL 60606
847-381-5465 Phone
847-381-4606 Fax
customerservice@codemap.com
      


User Information

Create New Account

Lost Password

Username:
Password:


Quick Links

PLA Codes

Laboratory Fee Schedule

2018

Physician Fee Schedule

2018

OPPS Fee Schedule

2018

ASC Fee Schedule

2018

APC Codes

2018

DRG Codes

2018

ASP Drug Pricing Files

October 2018
July 2018


CMS Transmittals



CPT® Proprietary Laboratory Analyses (PLA) Codes


PLA Code
Description
Test Name
Lab Name
Manufacturer
Effective Date
0001U
Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported PreciseType® HEA Test Immucor, Inc
11/30/2016
0002U
Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps PolypDX™ Atlantic Diagnostic Laboratories, LLC Metabolomic Technologies Inc
11/30/2016
0003U
Onocology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score Overa (OVA1 Next Generation) Aspira Labs, Inc Vermillion, Inc
11/30/2016
0005U
Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score ExosomeDx® Prostate(IntelliScore) Exosome Diagnostics, Inc Exosome Diagnostics, Inc
11/30/2016
0006U
Detection of interacting medications, substances, supplements and foods, 120 or more analytes, definitive chromatography with mass spectrometry, urine, description and severity of each interaction identified, per date of service Drug-drug, Drug-substance Identification and Interaction Aegis Sciences Corporation Drug-drug, Drug-substance Identification and Interaction
11/30/2017
0007U
Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service ToxProtect Genotox Laboratories LTD Genotox Laboratories LTD
11/30/2016
0008U
Helicobacter pylori detection and antibiotic resistance, DNA, 16S and 23S rRNA, gyrA, pbp1, rdxA and rpoB, next generation sequencing, formalin-fixed paraffin-embedded or fresh tissue or fecal sample, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin AmHPR H. Antibiotic Resistance Next Generation Sequencing Panel American Molecuclar Laboratories, Inc American Molecuclar Laboratories, Inc
11/30/2018
0009U
Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin-fixed paraffin-embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified DEPArray™ HER2 PacificDx PacificDx
11/30/2016
0010U
Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate Bacterial Strain Typing by Whole Genome Sequencing Mayo Clinic Mayo Clinic
11/30/2016
0011U
Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites Cordant CORE™ Cordant Health Solutions Cordant Health Solutions
11/30/2016
0012U
Germline disorders, gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood, report of specific gene rearrangement(s) MatePair Targeted Rearrangements, Congenital Mayo Clinic Mayo Clinic
11/30/2016
0013U
Oncology (solid organ neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, fresh or frozen tissue or cells, report of specific gene rearrangement(s) MatePair Targeted Rearrangements, Oncology Mayo Clinic Mayo Clinic
11/30/2016
0014U
Hematology (hematolymphoid neoplasia), gene rearrangement detection by whole genome next-generation sequencing, DNA, whole blood or bone marrow, report of specific gene rearrangement(s) MatePair Targeted Rearrangements, Hematologic Mayo Clinic Mayo Clinic
11/30/2016
0016U
Oncology (hematolymphoid neoplasia), RNA, BCR/ABL1 major and minor breakpoint fusion transcripts, quantitative PCR amplification, blood or bone marrow, report of fusion not detected or detected with quantitation BCR-ABL1 major and minor breakpoint fusion transcripts University of Iowa, Department of Pathology Asuragen
11/30/2016
0017U
Oncology (hematolymphoid neoplasia), JAK2 mutation, DNA, PCR amplification of exons 12-14 and sequence analysis, blood or bone marrow, report of JAK2 mutation not detected or detected JAK2 Mutation University of Iowa, Department of Pathology University of Iowa, Department of Pathology
11/30/2016
0018U
Oncology (thyroid), microRNA profiling by RT-PCR of 10 microRNA sequences, utilizing fine needle aspirate, algorithm reported as a positive or negative result for moderate to high risk of malignancy ThyraMIR Interpace Diagnostics Interpace Diagnostics
11/30/2016
0019U
Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin-embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents OncoTarget/OncoTreat Columbia University Department of Pathology and Cell Biology Darwin Health
11/30/2016
0021U
Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5’-UTR-BMI1, CEP 164, 3’-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNK2A2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score Apifiny® Armune BioScience Armune BioScience Inc
11/30/2016
0022U
Targeted genomic sequence analysis panel, non-small cell lung neoplasia, DNA and RNA analysis, 23 genes, interrogation for sequence variants and rearrangements, reported as presence/absence of variants and associated therapy(ies) to consider Oncomine™ Dx Target Test Thermo Fisher Scientific Thermo Fisher Scientific
11/30/2016
0023U
Oncology (acute myelogenous leukemia), DNA, genotyping of internal tandem duplication, p.D835, p.I836, using mononuclear cells, reported as detection or non-detection of FLT3 mutation and indication for or against the use of midostaurin LeukoStrat® CDx FLT3 Mutation Assay LabPMM LLC, an Invivoscribe Technologies, Inc Company Invivoscribe Technologies, Inc
11/30/2016
0024U
Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative GlycA Laboratory Corporation of America Laboratory Corporation of America
11/30/2017
0025U
Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative UrSure Tenofovir Quantification Test Synergy Medical Laboratories UrSure Inc
11/30/2017
0026U
Oncology (thyroid), DNA and mRNA of 112 genes, next-generation sequencing, fine needle aspirate of thyroid nodule, algorithmic analysis reported as a categorical result ("Positive, high probability of malignancy" or "Negative, low probability of malignancy") Thyroseq Genomic Classifier CBLPath, Inc University of Pittsburgh Medical Center
11/30/2017
0027U
JAK2 (Janus kinase 2) (eg, myeloproliferative disorder) gene analysis, targeted sequence analysis exons 12-15 JAK2 Exons 12 to 15 Sequencing Mayo Clinic Mayo Clinic
11/30/2017
0029U
Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823) Focused Pharmacogenomics Panel Mayo Clinic Mayo Clinic
11/30/2017
0030U
Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823) Warfarin Response Genotype Mayo Clinic Mayo Clinic
11/30/2017
0031U
CYP1A2 (cytochrome P450 family 1, subfamily A, member 2) (eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7) Cytochrome P450 1A2 Genotype Mayo Clinic Mayo Clinic
11/30/2017
0032U
COMT (catechol-O-methyltransferase) (eg, drug metabolism) gene analysis, c.472G>A (rs4680) variant Catechol-O-Methyltransferase (COMT) Genotype Mayo Clinic Mayo Clinic
11/30/2017
0033U
HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G]) Serotonin Receptor Genotype (HTR2A and HTR2C) Mayo Clinic Mayo Clinic
11/30/2017
0034U
TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5) Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15) Genotyping Mayo Clinic Mayo Clinic
11/30/2017
0035U
Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative Real-time quaking-induced conversion for prion detection (RT-QuIC) National Prion Disease Pathology Surveillance Center
11/30/2017
0036U
Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses EXaCT-1 Whole Exome Testing Lab of Oncology-Molecular Detection Weill Cornell Medicine-Clinical Genomics Laboratory
11/30/2017
0037U
Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden FoundationOne CDx™ (F1CDx) Foundation Medicine, Inc Foundation Medicine, Inc
11/30/2017
0038U
Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay InSource Diagnostics
11/30/2017
0039U
Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity Anti-dsDNA, High Salt/Avidity University of Washington, Department of Laboratory Medicine Bio-Rad
11/30/2017
0040U
BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative MRDx BCR-ABL Test MolecularMD MolecularMD
11/30/2017
0041U
Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM Lyme ImmunoBlot IgM IGeneX Inc ID-FISH Technology Inc (ASR) (Lyme ImmunoBlot IgM Strips Only)
11/30/2017
0042U
Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG Lyme ImmunoBlots IgG IGeneX Inc ID-FISH Technology Inc (ASR) (Lyme ImmunoBlot IgG Strips Only)
11/30/2017
0043U
Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM Tick-Borne Relapsing Fever Borrelia (TBRF) ImmunoBlots IgM Test IGeneX Inc ID-FISH Technology Inc (Provides TBRF ImmunoBlot IgM Strips)
11/30/2017
0044U
Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG Tick-Borne Relapsing Fever Borrelia (TBRF) ImmunoBlots IgG Test IGeneX Inc ID-FISH Technology Inc (Provides TBRF ImmunoBlot IgG Strips)
11/30/2017
0045U
Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score The Oncotype DX® Breast DCIS Score™ Test Genomic Health, Inc Genomic Health, Inc
11/30/2017
0046U
FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative FLT3 ITD MRD by NGS LabPMM LLC, an Invivoscribe Technologies, Inc Company LabPMM LLC, an Invivoscribe Technologies, Inc Company
11/30/2017
0047U
Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score Oncotype DX Genomic Prostate Score Genomic Health, Inc Genomic Health, Inc
11/30/2017
0048U
Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s) MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center
11/30/2017
0049U
NPM1 (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative NPM1 MRD by NGS LabPMM LLC, an Invivoscribe Technologies, Inc Company LabPMM LLC, an Invivoscribe Technologies, Inc Company
11/30/2017
0050U
Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements MyAML NGS Panel LabPMM LLC, an Invivoscribe Technologies, Inc Company LabPMM LLC, an Invivoscribe Technologies, Inc Company
11/30/2017
0051U
Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service UCompliDx Elite Medical Laboratory Solutions, LLC (LDT) Elite Medical Laboratory Solutions, LLC
11/30/2017
0052U
Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation VAP Cholesterol Test VAP Diagnostics Laboratory, Inc VAP Diagnostics Laboratory, Inc
11/30/2017
0053U
Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade Prostate Cancer Risk Panel Mayo Clinic, Laboratory Developed Test Mayo Clinic
11/30/2017
0054U
Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service AssuranceRx Micro Serum Firstox Laboratories, LLC Firstox Laboratories, LLC
11/30/2017
0055U
Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma myTAIHEART TAI Diagnostics, Inc TAI Diagnostics, Inc
11/30/2017
0056U
Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s) MatePair Acute Myeloid Leukemia Panel Mayo Clinic, Laboratory Developed Test Mayo Clinic
11/30/2017
0057U
Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank RNA-Sequencing by NGS OmniSeq, Inc, Life Technologies Corporation OmniSeq, Inc, Life Technologies Corporation
11/30/2017
0058U
Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative Merkel SmT Oncoprotein Antibody Titer University of Washington, Department of Laboratory Medicine University of Washington, Department of Laboratory Medicine
11/30/2017
0059U
Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative Merkel Virus VP1 Capsid Antibody University of Washington, Department of Laboratory Medicine University of Washington, Department of Laboratory Medicine
11/30/2017
0060U
Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood Twins Zygosity PLA Natera, Inc Natera, Inc
11/30/2017
0061U
Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis Transcutaneous multispectral measurement of tissue oxygenation and hemoglobin using spatial frequency domain imaging (SFDI) Modulated Imaging, Inc Modulated Imaging, Inc
11/30/2017
0062U
Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score SLE-key® Rule Out Veracis Inc Veracis Inc
11/30/2017
0063U
Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder NPDX ASD ADM Panel I Stemina Biomarker Discovery, Inc Stemina Biomarker Discovery, Inc d/b/a NeuroPointDX
11/30/2017
0064U
Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative BioPlex 2200 Syphilis Total & RPR Assay Bio-Rad Laboratories Bio-Rad Laboratories
11/30/2017
0065U
Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR) BioPlex 2200 RPR Assay Bio-Rad Laboratories Bio-Rad Laboratories
11/30/2017
0066U
Placental alpha-micro globulin-1 (PAMG-1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen PartoSure™ Test Parsagen Diagnostics, Inc Parsagen Diagnostics, Inc, a QIAGEN Company
11/30/2017
0067U
Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score BBDRisk Dx™ Silbiotech, Inc Silbiotech, Inc
11/30/2017
0068U
Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species MYCODART Dual Amplification Real Time PCR Panel for 6 Candida species RealTime Laboratories, Inc RealTime Laboratories, Inc
11/30/2017
0069U
Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score miR-31now™ GoPath Laboratories GoPath Laboratories
11/30/2017
0070U
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN) CYP2D6 Common Variants and Copy Number Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0071U
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure) CYP2D6 Full Gene Sequencing Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0072U
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure) CYP2D6-2D7 Hybrid Gene Targeted Sequence Analysis Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0073U
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure) CYP2D7-2D6 Hybrid Gene Targeted Sequence Analysis Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0074U
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure) CYP2D6 trans-duplication/multiplication non-duplicated gene targeted sequence analysis Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0075U
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5’ gene duplication/multiplication) (List separately in addition to code for primary procedure) CYP2D6 5’ gene duplication/multiplication targeted sequence analysis Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0076U
CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3’ gene duplication/ multiplication) (List separately in addition to code for primary procedure) CYP2D6 3’ gene duplication/multiplication targeted sequence analysis Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0077U
Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry Mayo Clinic Mayo Clinic Laboratory Developed Test
11/30/2017
0078U
Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder INFINITI® Neural Response Panel PersonalizeDx Labs AutoGenomics Inc
11/30/2017
0079U
Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification ToxLok™ InSource Diagnostics InSource Diagnostics
11/30/2017
0080U
Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy BDX-XL2, Biodesix®, Inc Biodesix®, Inc Biodesix®, Inc
11/30/2018
0081U
Oncology (uveal melanoma), mRNA, gene-expression profiling by real-time RT-PCR of 15 genes (12 content and 3 housekeeping genes), utilizing fine needle aspirate or formalin-fixed paraffin-embedded tissue, algorithm reported as risk of metastasis DecisionDx®-UM Castle Biosciences, Inc Castle Biosciences, Inc
11/30/2018
0082U
Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service NextGen Precision™ Testing Precision Diagnostics LBN Precision Toxicology, LLC Precision Diagnostics LBN Precision Toxicology, LLC
11/30/2018
0083U
Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations Onco4D™ Animated Dynamics, Inc Animated Dynamics, Inc
11/30/2018



CodeMap® is a Registered Trademark of Wheaton Partners, LLC.